Age-related Macular Degeneration Market Size & Growth Forecast 2027–2036, By Segments (Product, Disease, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Age-related Macular Degeneration Market size was more than USD 12.5 billion in 2026 and is set to grow at a 8.55% CAGR between 2027 and 2036, attaining USD 28.39 billion by 2036. The industry revenue for 2027 is calculated at USD 13.4 billion.

• Base Year Value (2026): USD 12.5 billion
• CAGR (2027-2036): 8.55%
• Forecast Year Value (2036): USD 28.39 billion
• Historical Data Period: 2022-2026
• Largest Region: North America
• Forecast Period: 2027-2036

Age-related Macular Degeneration Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America held a 57.02% market share in 2026, supported by established retinal care pathways, broad specialist access, routine diagnostic imaging, and strong treatment uptake backed by reimbursement systems.
  • Europe is projected to grow at a 9.27% CAGR, fueled by wider adoption of advanced retinal diagnostics, expanding treatment access, and earlier intervention supported by structured patient management.

• Segment Momentum:

  • Eylea held a 50.56% market share in 2026, supported by broad physician familiarity, routine integration into retinal care pathways, and consistent use in anti-VEGF treatment, reinforcing prescribing stability.
  • Dry AMD is the fastest-growing disease segment as attention shifts toward earlier disease management and expanding therapies for patients with historically limited treatment options, increasing commercial momentum.

• Market Expansion Drivers:

  • Rising aging population driving higher prevalence of age-related vision disorders.
  • Increasing pipeline approvals of anti-VEGF therapies improving treatment accessibility.
  • Expanding home-based retinal monitoring and tele-ophthalmology improving early diagnosis rates.

• Leading Market Participants:

  Prominent companies in the age-related macular degeneration market include F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Regeneron Pharmaceuticals, Inc. (United States), Bayer AG (Germany), Pfizer Inc. (United States), Samsung Bioepis Co., Ltd. (South Korea), Amgen Inc. (United States), Biogen Inc. (United States), Bausch Health Companies Inc. (Canada), Apellis Pharmaceuticals, Inc. (United States).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2026 Market Size: USD 12.5 billion
  • 2027 Estimated Market Size: USD 13.4 billion.
  • Projected Market Size: USD 28.39 billion by 2036
  • Growth Forecasts: 8.55% CAGR (2027-2036)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Europe
  • Core Revenue Segment: Eylea (Product) | Wet AMD (Disease) | Hospital Pharmacy (Distribution Channel)
  • Emerging Opportunity Segment: Beovu (Product) | Dry AMD (Disease) | Specialty Pharmacy (Distribution Channel)

Market Growth Drivers and Industry Trends

Rising aging population driving higher prevalence of age-related vision disorders

The growing proportion of older adults is increasing the prevalence of retinal and vision disorders, creating a larger patient pool for diagnosis and treatment. In the age-related macular degeneration market, demographic aging is particularly significant because the risk of developing degenerative changes in the macula increases with advancing age, while longer life expectancy allows more individuals to live with age-associated visual impairment. Rising awareness among older populations and caregivers is also encouraging individuals to seek ophthalmic evaluations when vision changes emerge, supporting greater identification of early and intermediate stages of the disease. Increased demand for specialist consultations, retinal imaging, monitoring, and therapeutic interventions is consequently expanding the need for comprehensive management of age-related vision disorders.

Increasing pipeline approvals of anti-VEGF therapies improving treatment accessibility

The continued development and approval of anti-VEGF therapies are broadening treatment options for patients with neovascular forms of the disease and improving access to established mechanisms of retinal care. Within the age-related macular degeneration market, expanding therapeutic pipelines can support greater physician choice by introducing additional treatment alternatives, dosing approaches, and formulations that may address varying patient needs. Broader availability of anti-VEGF therapies can also strengthen treatment adoption by enabling clinicians to select therapies according to disease severity, treatment response, administration requirements, and patient preferences. As therapeutic options become more accessible, patients who previously faced barriers related to treatment availability or continuity of care can have greater opportunities to receive disease-modifying intervention.

Expanding home-based retinal monitoring and tele-ophthalmology improving early diagnosis rates

The integration of remote retinal monitoring technologies and tele-ophthalmology is making ongoing eye health assessment more accessible beyond conventional clinical settings. For the age-related macular degeneration market, home-based monitoring can help identify changes in visual function or retinal condition between scheduled ophthalmology visits, particularly among older individuals who may face mobility or transportation challenges. Tele-ophthalmology also facilitates the exchange of patient information and retinal assessments with specialists, supporting faster evaluation of suspicious changes and more timely referrals for further examination. Greater use of remote monitoring can strengthen continuity of care and encourage earlier recognition of disease progression, particularly for patients requiring regular surveillance.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising aging population driving higher prevalence of age-related vision disorders	2.20%	High	North America, Europe	High	Near Term
Increasing pipeline approvals of anti-VEGF therapies improving treatment accessibility	1.80%	High	North America	High	Near Term
Expanding home-based retinal monitoring and tele-ophthalmology improving early diagnosis rates	1.50%	Moderate	North America, Asia Pacific	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Europe (Fastest-Growing Region)

In the age-related macular degeneration market, North America held the largest share of 57.02% in 2026, supported by advanced ophthalmic care infrastructure, high awareness of retinal disorders, and broad access to diagnostic and therapeutic services. The region benefits from strong adoption of innovative retinal imaging technologies and established treatment pathways for patients requiring long-term disease management. An aging population, increasing emphasis on early detection, and greater utilization of specialized eye-care services continue to sustain demand. Reimbursement mechanisms and ongoing investment in ophthalmology research and healthcare infrastructure further strengthen North America's market position.

Europe is emerging as the fastest-growing region, driven by its aging demographic profile and increasing focus on preserving vision among older adults. Healthcare systems across the region are placing greater emphasis on early diagnosis and effective management of chronic eye disorders, supporting demand for retinal screening, imaging, and treatment services. Improvements in ophthalmic technologies and expanding access to specialized care are also contributing to market development. In addition, growing awareness of age-related vision impairment among patients and healthcare professionals is encouraging earlier intervention, while efforts to improve outcomes for chronic retinal conditions are supporting sustained market expansion.

Key Country Insights

United States

Advanced Treatment Adoption

The U.S. age-related macular degeneration market emphasizes timely diagnosis and broad adoption of innovative retinal therapies across specialized ophthalmology networks. Healthcare providers continue integrating advanced imaging technologies to improve treatment planning and patient monitoring.

Japan

Aging Care Focus

Japan places significant emphasis on age-related macular degeneration management as demographic trends increase demand for sustained retinal care. Ophthalmology providers continue strengthening early detection programs and personalized treatment approaches to preserve visual function.

South Korea

Digital Retina Services

South Korea is expanding digital ophthalmology capabilities to support earlier identification and ongoing management of age-related macular degeneration. Healthcare providers increasingly integrate advanced imaging and specialized retinal services into routine eye care practices.

Germany

Precision Ophthalmic Care

Germany prioritizes comprehensive management of age-related macular degeneration through specialized retinal care and advanced diagnostic capabilities. Clinical practices increasingly focus on treatment optimization, long-term patient monitoring, and efficient coordination across ophthalmology centers.

France

Integrated Vision Management

France advances coordinated care for age-related macular degeneration by strengthening collaboration between ophthalmology specialists and long-term patient management services. Clinical priorities include timely intervention, consistent follow-up, and optimized therapeutic decision-making.

Italy

Specialist Retina Networks

Italy continues reinforcing specialized retinal care networks to improve access to age-related macular degeneration diagnosis and treatment. Healthcare providers prioritize efficient patient pathways, regular disease monitoring, and adoption of contemporary ophthalmic treatment protocols.

Segment Leadership and Growth Trends

 

Product Segment Analysis: Eylea (Largest Segment) vs Beovu (Fastest-Growing Segment)

The eylea segment held the largest position in the age-related macular degeneration market in 2026, representing a 50.56% share. Its established role in the management of retinal vascular conditions and its use across appropriate patient populations support sustained clinical adoption. Continued demand for anti-VEGF therapies, along with the need for effective approaches to reduce abnormal retinal fluid and preserve vision, contributes to the product's strong market presence.

Beovu represents the fastest-growing product segment, supported by its role as an anti-VEGF therapy and its potential to provide durable disease management for appropriate patients. Its clinical profile can support treatment strategies aimed at reducing the burden associated with frequent retinal disease management, while continued interest in therapies that balance efficacy, dosing considerations, and patient convenience creates opportunities for broader adoption.

Disease Segment Analysis: Wet AMD (Largest Segment) vs Dry AMD (Fastest-Growing Segment)

Wet AMD held the largest share of the age-related macular degeneration market in 2026, driven by the need for active pharmacological management of abnormal blood-vessel growth and fluid accumulation in the retina. The availability and established use of anti-VEGF treatment approaches support continued clinical demand, while the potentially rapid impact of neovascular disease on vision reinforces the importance of timely diagnosis and treatment.

The dry AMD segment is expanding at the fastest pace as growing attention to retinal aging, disease detection, and progression management increases the focus on this form of the condition. Advances in understanding retinal degeneration are encouraging greater investment in therapeutic approaches for dry disease, while increasing awareness among patients and healthcare professionals is supporting earlier identification and ongoing monitoring.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Eylea, Lucentis, Beovu, Others	Eylea	Beovu
Disease	Wet AMD, Dry AMD	Wet AMD	Dry AMD
Distribution Channel	Hospital Pharmacy, Specialty Pharmacy, Online Pharmacy	Hospital Pharmacy	Specialty Pharmacy

Competitive Landscape and Market Positioning

Prominent players in the age-related macular degeneration market:

1. F. Hoffmann-La Roche Ltd (Switzerland)

2. Novartis AG (Switzerland)

3. Regeneron Pharmaceuticals Inc. (United States)

4. Bayer AG (Germany)

5. Pfizer Inc. (United States)

6. Samsung Bioepis Co. Ltd. (South Korea)

7. Amgen Inc. (United States)

8. Biogen Inc. (United States)

9. Bausch Health Companies Inc. (Canada)

10. Apellis Pharmaceuticals Inc. (United States)

The age-related macular degeneration market is witnessing strong momentum driven by advances in targeted and regenerative treatment approaches. Research activity is intensifying around novel therapeutic pathways aimed at slowing disease progression and improving vision outcomes. Collaborative development efforts and pipeline expansion strategies are accelerating innovation cycles. Meanwhile, ongoing restructuring through acquisitions and pipeline consolidation is reshaping competitive positioning, while new therapies continue to enter clinical and commercial stages.

Industry Development/News

Company Name	Date	Key Development
Merck & Co.	Feb-24	Merck & Co. acquired EyeBio in a deal valued at up to $3 billion, re-entering the ophthalmology sector. This acquisition integrates significant assets targeting retinal diseases, including age-related macular degeneration, into Merck’s pipeline, representing a major strategic expansion of its therapeutic portfolio and competitive positioning in the eye disease market.
Science Corporation	Apr-24	Science Corporation secured $230 million in financing to accelerate the regulatory progression and commercialization of its Prima vision restoration device. This funding is critical for advancing the technology, which is specifically designed to address unmet clinical needs for patients suffering from late-stage macular degeneration.
Eli Lilly and Company	Mar-24	Eli Lilly and Company expanded its ophthalmology and gene therapy capabilities through strategic agreements with MeiraGTx and Adverum. These partnerships are designed to bolster the company’s internal pipeline for advanced retinal disease therapies, positioning Lilly to better compete in the growing market for age-related macular degeneration treatments.
Genentech (Roche)	Jul-24	Genentech, a member of the Roche Group, successfully reintroduced the Susvimo ocular implant for the treatment of neovascular age-related macular degeneration in the U.S. market. This reintroduction restores a key long-acting therapeutic option for patients, enhancing the company’s ability to maintain its market share in the retinal disease treatment landscape.
Sanofi	Mar-24	Sanofi received FDA Fast Track designation for its investigational gene therapy candidate, SAR402663, for neovascular age-related macular degeneration. This regulatory milestone supports accelerated clinical development and engagement, reflecting a strategic push to introduce a one-time, durable intravitreal treatment option to a highly competitive, injection-heavy market segment.
Outlook Therapeutics	Mar-24	Outlook Therapeutics announced positive Phase 3 trial results for its ONS-5010 therapeutic candidate and finalized additional funding to support regulatory resubmission. These developments are essential for the company’s path toward commercialization and entry into the wet age-related macular degeneration market, directly impacting its future competitive standing.
Character Biosciences	Mar-24	Character Biosciences successfully completed an oversubscribed Series B financing round to drive the development of its precision medicine pipeline for age-related macular degeneration. The injection of capital allows the firm to advance its technology platform, which aims to provide personalized therapeutic approaches for specific patient populations.
Roche Korea	Apr-24	Roche Korea secured national health insurance reimbursement for the prefilled syringe formulation of Vabysmo. This regulatory success enables an immediate commercial launch in the region, significantly improving treatment access and logistics for patients with retinal diseases, thereby enhancing Roche's competitive position within the regional ophthalmology market.
Ikarovec	Apr-24	Ikarovec established a strategic partnership with VectorBuilder to facilitate the development of an ophthalmic gene therapy platform designed for in-office physician administration. This collaboration focuses on simplifying the delivery model for gene therapies, which could fundamentally alter market access and patient adoption rates for long-term retinal disease management.
Ocular Therapeutix	Apr-24	Ocular Therapeutix bolstered its commercial leadership team by recruiting key talent formerly associated with the Eylea launch. This strategic hiring reflects the company’s effort to refine its market positioning and commercial readiness as it prepares to compete against established therapies within the high-value retinal disease treatment space.